Treatment of Tenecteplase-Induced Angioedema in Acute Ischemic Stroke
Treat tenecteplase-induced angioedema using the same protocol established for alteplase-induced angioedema, as both are tissue plasminogen activators with identical mechanisms of bradykinin-mediated angioedema. 1
Immediate Airway Management
Airway assessment and protection is the first priority, as progression can be rapid and life-threatening. 1
- Endotracheal intubation may not be necessary if edema is limited to the anterior tongue and lips only. 1
- High risk for intubation exists when edema involves the larynx, palate, floor of mouth, or oropharynx, especially with rapid progression within 30 minutes. 1
- Awake fiberoptic intubation is the optimal technique when intubation is required. 1
- Avoid nasotracheal intubation when possible due to epistaxis risk post-thrombolytic therapy, though it may be necessary. 1
- Cricothyroidotomy is rarely needed but is also problematic after thrombolytic administration due to bleeding risk. 1
Pharmacological Intervention Protocol
First-Line Medications (Administer Immediately)
Discontinue the tenecteplase infusion immediately (though tenecteplase is typically given as a single bolus, ensure no additional dosing). 1
Hold all ACE inhibitors, as concurrent use significantly increases angioedema risk. 1
Administer the following medications in sequence:
Second-Line Therapy (If Angioedema Progresses)
If there is further increase in angioedema after initial treatment:
- Epinephrine (0.1%) 0.3 mL subcutaneously OR 0.5 mL by nebulizer 1
Third-Line Therapy (Refractory Cases)
For refractory angioedema unresponsive to antihistamines and corticosteroids:
- Icatibant (selective bradykinin B2 receptor antagonist): 30 mg (3 mL) subcutaneously in the abdominal area. Additional 30 mg injections may be given at 6-hour intervals, not exceeding 3 injections in 24 hours. 1
- Plasma-derived C1 esterase inhibitor (20 IU/kg) has been successfully used in hereditary angioedema and ACEI-related angioedema. 1
Pathophysiological Considerations
Tenecteplase-induced angioedema is primarily bradykinin-mediated, not histamine-mediated, which explains why antihistamines and corticosteroids alone may be insufficient. 2 The mechanism involves activation of the fibrinolytic pathway and contact activation system, leading to increased bradykinin levels. 3, 2
This is distinct from allergic angioedema (which presents with urticaria), and the FDA label for tenecteplase acknowledges hypersensitivity reactions including angioedema as a known adverse effect. 4
Clinical Monitoring
Monitor patients treated with tenecteplase during and for several hours after administration for signs of angioedema development. 4
Typical onset is during or within 1-2 hours after tenecteplase administration. 5, 3, 6
Important Caveats
The evidence base for C1 esterase inhibitors and icatibant in thrombolytic-associated angioedema is limited, consisting primarily of case reports and expert opinion (Class IIb, Level of Evidence C-EO). 1, 5 However, these agents target the bradykinin pathway, which is the primary pathophysiological mechanism. 2
Case reports demonstrate variable response to C1 esterase inhibitors, with some patients requiring intubation despite treatment. 5 Therefore, do not delay airway management while waiting for these medications to take effect.
Risk factors for thrombolytic-associated angioedema include:
- Concurrent ACE inhibitor use 1, 3
- Female gender 3
- Diabetes 3
- Infarcts involving the insula and frontal cortex 3
The incidence of thrombolytic-induced angioedema ranges from 0.2% to 5.1%, making it a rare but serious complication. 6